None
No disclosed counterparties: XYL.
| Stage | XYL | % of rev | FLS | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $2.2B | 100.00% | $1.2B | 100.00% | XYL ×1.78 |
| Gross profit | $907M | 41.21% | $414M | 33.48% | XYL +7.7pp |
| Operating income | $385M | 17.49% | $155M | 12.49% | XYL +5.0pp |
| Pre-tax income | $365M | 16.58% | $122M | 9.87% | XYL +6.7pp |
| Net income | $288M | 13.08% | $107M | 8.65% | XYL +4.4pp |
| Stage | XYL | FLS | Gap · A − B |
|---|---|---|---|
| Revenue | $2.2B100.00% | $1.2B100.00% | XYL ×1.78 |
| Gross profit | 41.21%$907M | 33.48%$414M | XYL +7.7pp |
| Operating income | 17.49%$385M | 12.49%$155M | XYL +5.0pp |
| Pre-tax income | 16.58%$365M | 9.87%$122M | XYL +6.7pp |
| Net income | 13.08%$288M | 8.65%$107M | XYL +4.4pp |